Tipsheet
What matters at India’s listed companies
Earnings · CDMO · Mid cap

Supriya Lifescience profit jumps 47% in Q4

The pharmaceutical company closed the fiscal year with a 50% revenue surge in the final quarter, reaching ₹276.53 crore.

1 earlier story on Supriya Lifescience Ltd.
Mkt cap₹6,497 cr
P/E35.07×
ROE18.86%
Debt / eq.0.00
Div yld0.13%
₹74.23 cr Net profit for the quarter ended March 31, 2026.

What's new

  • Q4 revenue climbed 50% year-on-year to ₹276.53 crore.
  • Full-year revenue reached ₹827.88 crore, an 18.9% increase.
  • Board recommended a final dividend of ₹1 per share.

Why this matters

Supriya Lifescience finished the year with a sharp acceleration in its final quarter. The 47% profit growth in Q4 significantly outpaced the 11.3% growth recorded for the full year, suggesting a strong finish to FY26.

What we're watching

  • Whether the Q4 growth rate is sustainable in the coming fiscal year.
  • Shareholder approval for the proposed dividend.
  • Management commentary on the drivers behind the Q4 revenue spike.

The full read

Supriya Lifescience closed FY26 with a surge in its final quarter. Revenue for the period ended March 31, 2026, hit ₹276.53 crore, a 50% increase over the same period last year. Net profit followed a similar trajectory, rising 47% to ₹74.23 crore. These quarterly figures represent a significant acceleration compared to the full-year results, where revenue grew 18.9% to ₹827.88 crore and net profit rose 11.3% to ₹209.12 crore. The board has proposed a final dividend of ₹1 per share, pending shareholder approval. The company's ability to scale its bottom line in the final quarter at a rate far exceeding its annual average is the primary takeaway from these audited results.

Questions answered

What were the full-year financial results for FY26?
The company reported annual revenue of ₹827.88 crore and a net profit of ₹209.12 crore.
How did the fourth quarter compare to the full-year performance?
The fourth quarter showed stronger momentum with revenue and profit growth of 50% and 47% respectively, compared to full-year growth rates of 18.9% and 11.3%.
Is there a dividend for shareholders?
The board has recommended a final dividend of ₹1 per equity share, which remains subject to approval at the next annual general meeting.
Mentioned: Supriya Lifescience
Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.

  1. 27 May 2026 · 6:55 PM IST Supriya Lifescience profit jumps 47% in Q4
  2. today Supriya Lifescience ends FY26 with a 50% revenue jump in Q4